Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5142449 | 1.00 | MEN1 (0.44) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL3459106 | 1.00 | MEN1 (0.44) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL5316986 | 0.84 | GRM2 (0.45) | MEN1KMT2ANPC1RAB9ATAAR1 | |
| SCHEMBL4550640 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2ATDP1ALOX5ALDH1A1 | |
| SCHEMBL997079 | 0.80 | L3MBTL1 (0.41) | KMT2AOPRM1PKML3MBTL1 | |
| SCHEMBL162237 | 0.80 | L3MBTL1 (0.41) | KMT2AOPRM1PKML3MBTL1 | |
| SCHEMBL2968353 | 0.80 | L3MBTL1 (0.41) | KMT2AOPRM1PKML3MBTL1 | |
| SCHEMBL5425735 | 0.77 | TAAR1 (0.47) | MEN1KMT2AOPRM1TAAR1OPRD1 | |
| SCHEMBL9054232 | 0.75 | CTSD (0.43) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL16908761 | 0.73 | C5AR1 (0.51) | MEN1KMT2ANPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910317-B1 | 1-AMINO LINKED COMPOUNDS | LILLY CO ELI (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2446025-A2 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | Codexis, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| WO-2011080562-A1 | NOVEL AZA-PEPTIDES CONTAINING 2,2-DISUBSTITUTED CYCLOBUTYL AND/OR SUBSTITUTED ALKOXY BENZYL DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011005527-A2 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | CODEXIS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-2069303-A2 | ANTIVIRAL PROTEASE INHIBITORS | Gilead Sciences, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| WO-2008011117-A2 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207735-A1 | 1-Amino Linked Compounds | DPP4, DPP3, DPP9 | MEN1 3551/4885KMT2A 2916/4885NPC1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.